Clobetasol Propionate Foam, 0.05%

[1]  H. Skelton,et al.  A clonal cutaneous CD30+ lymphoproliferative eruption in a patient with evidence of past exposure to hepatitis E , 2000, International journal of dermatology.

[2]  J. Hannigan,et al.  Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery , 2000, International journal of dermatology.

[3]  S. Feldman,et al.  Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. , 2000, Journal of the American Academy of Dermatology.

[4]  J. Hannigan,et al.  Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy , 1999, International journal of dermatology.

[5]  M. Lebwohl,et al.  Duration of remission of psoriasis therapies. , 1999, Journal of the American Academy of Dermatology.

[6]  M. Schultzberg,et al.  Somatostatin- and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calciprotriol treatment. , 1999, Acta dermato-venereologica.

[7]  M. Gordon.  The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses. , 1998, Clinical therapeutics.

[8]  M. Lebwohl,et al.  Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. , 1997, Cutis.

[9]  G. Singh,et al.  Tachyphylaxis to histamine-induced wheal suppression by topical 0.05% clobetasol propionate in normal versus croton oil-induced dermatitic skin. , 1996, Dermatology.

[10]  J. Weiss,et al.  Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. , 1995, Clinical therapeutics.

[11]  M. Kietzmann,et al.  Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. , 1995, Dermatology.

[12]  T. Salo,et al.  Demonstration of 72-kDa and 92-kDa forms of type IV collagenase in human skin: variable expression in various blistering diseases, induction during re-epithelialization, and decrease by topical glucocorticoids. , 1993, The Journal of investigative dermatology.

[13]  Oakley Rh,et al.  Homologous down regulation of the glucocorticoid receptor: the molecular machinery. , 1993 .

[14]  E. Farber,et al.  Natural history and treatment of scalp psoriasis. , 1992, Cutis.

[15]  M. Kietzmann,et al.  Steroid-induced dermal thinning: discontinuous application of clobetasol-17-propionate ointment. , 1992, Dermatology.

[16]  M. Lebwohl,et al.  A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. , 1991, Journal of the American Academy of Dermatology.

[17]  J. Mooney,et al.  Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function. , 1987, Journal of the American Academy of Dermatology.